Adjuvant Capital

The Global Health Investment Corporation (GHIC) is a health impact venture firm focused on investing in transformational technologies and products that will enable a healthier world and safer future for all. A pioneer of impact investing in global health, GHIC has been financing innovation for nearly a decade. For nearly a decade, the Global Health Investment Corporation (GHIC) has been financing innovations in healthcare and life sciences. We pursue a double bottom line investment model to accelerate the development of technologies with the potential to both improve public health and generate financial returns. We strive to ensure that the technologies we support will be developed and made accessible to people who need them. The COVID-19 pandemic clearly demonstrates how interconnected health outcomes are throughout the world. But it is just the latest example. Outbreaks of existing and emerging infectious diseases are inevitable, but we must stop them from becoming pandemics. Our goal is to address today’s global health and health security challenges, anticipate those of tomorrow, and invest in innovations that will lead to a healthier and safer world - for all of us. Our new global health security venture fund will be launched in partnership with BARDA, which is providing funding to GHIC of up to $500M over 10 years to accelerate the development and commercialization of technologies to address global public health emergencies, such as pandemics and other health security threats. GHIC is growing its team to become the preeminent health impact platform and scaling across a number of roles to support the expansion of its investment portfolio and other programmatic activities.

Cross-Border Impact Ventures is an impact venture capital firm on a mission to revolutionize venture capital investing in health technology. We work with visionary teams to leapfrog access to world leading affordable technologies for women, children and adolescents. Health technologies are more scalable than ever before. The time is now to take a global tailored approach in this sector. OUR INVESTMENT UNIVERSE We look for audacious companies commercializing globally relevant medical devices, diagnostics, therapeutics and digital health innovations that are prioritizing huge market opportunities in women, children and adolescent health. We value real world and clinical data. We focus on 4 key sectors: Sexual and reproductive health, Maternal, newborn and child health, General health, including chronic diseases, and Health software infrastructure. We invest in companies addressing gender health inequalities. Positive impact and financial returns are not mutually exclusive. We seek opportunities that offer both high impact & high returns. OUR IMPACT We believe good health is a right that should not be restricted by gender, age, race, wealth and borders. We hold ourselves to the highest standard of impact investing and implement recognized impact management processes. We invest with a gender and diversity lens. WE ARE ENABLERS We are specialists in women, children and adolescent health with deep expertise in health technology. We are hands-on investors and support our exceptional management teams with access to new markets, unique forms of capital and health technology expertIse in North America, Europe as well as global markets. WE UNLOCK GLOBAL IMPACT OPPORTUNITIES Cutting edge technologies take decades to reach underserved communities. We work with management teams to fast track the process.

Tenmile is a dedicated health technology investment business owned by Tattarang, one of Australia’s largest private investment groups. With an initial capital allocation of $250 million, we act fast and with confidence, investing without some of the constraints of other venture capital funds. Focused on supporting and building early-stage companies, we have the know-how, networks and evergreen capital to partner through all stages of growth. With team members in Perth, Sydney and San Franscisco, we seek to address unmet needs in human health and support the development of a globally significant health science and technology sector in Australia. Healthcare is a global challenge requiring global solutions. Building an Australian sector means understanding international markets and trends and bringing international know-how and technology to Australian patients. We leverage extensive local and international networks to help establish and promote the companies in which we invest, connecting them to resources that will fuel their growth. Our remit is broad, spanning all health technology and sciences with some specific areas of interest in digital health, immunology, oncology, microbial resistance and the microbiome. If you have a good idea and a strong business case that helps solve an unmet medical need, promotes health equity or delivers affordable, sustainable healthcare, we encourage you to apply! Our team is driven for your success. Tenmile’s team of business builders, specialists and experienced investors believe in the power of health technology to improve quality of life and drive better health outcomes for all. Its trusted advisors and domain experts are united by a quest to develop and scale a health technology and sciences sector in Australia and inspire future generations of visionary innovators. OUR VALUES Tenmile is driven by a set of values Humility: Be vulnerable, take risks to trust others. Courage and Determination: NEGU – we never ever give up. Empowerment: Go to your leader for advice, not permission. Enthusiasm: Be the most positive person in the room. Family: Support each other, always be kind. Frugality: Think of ways we can do things better, faster, cheaper, safer. Generating Ideas: Always be on the lookout for breakthroughs. Integrity: Do what you say you’re going to do. Safety: Look out for your mates and yourself. Stretch Targets: Always be uncomfortable with your level of challenge. DIVERSITY Diverse management teams make good investments. For every investment we make, we seek to understand the differential impact of a product or service by gender. We actively support female founders and encourage female participation in board and executive roles, in line with our company values. In conjunction with Tattarang, we are thrilled to be a corporate partner in Women in Leadership Development (WiLD), a program providing Australian women in science, technology, engineering and maths (STEM) with the qualifications, skills and networks needed to attain senior leadership and board positions. ESG At Tenmile we not only consider the Environmental, Social and Governance (ESG) risks and opportunities associated with each investment, but we also encourage and support our investees to improve their ESG risk management and develop more sustainable business practices. To assess overall performance of potential investees, ESG factors are considered (in addition to financial performance) at the first stage of the investment lifecycle and formally at investment decision stage. This informs our ongoing investment strategy, including active monitoring, management and reporting. For our earliest stage companies and founders, we can offer advice on sustainability and ESG opportunities, so they are incorporated from the beginning.

Mirae Asset Capital Life Science was formed in 2023 as a joint venture between Mirae Asset Capital and Mirae Asset Global Investments. It is the first and only U.S. affiliate for Mirae Asset dedicated to investment in Life Science. Near-Term ValueThe majority of our investments will be Series A/B and entering the clinic within a few years to generate real value with clinical proof of concept We believe companies at this stage maximize returns given the risk; we remain open to seed opportunities where there is a clear path to value and Series C opportunities if the valuation and resulting equity ownership support meaningful returns to our investors We aim to find the right mix between first-in-class and best-in-class assets with meaningful market share and evaluate both platform and single asset approaches Calculated RiskWe are modality agnostic when it comes to therapeutics and incredibly opportunistic with diagnostics Our interest in digital health involves using AI/ML tools (e.g. quantum computing, generative biology/chemistry) for drug discovery or protein engineering We co-invest with top-tier life science investors who we know and have worked with before and leverage our operational experience to find strong management teams with excellent track records relevant to the company they are building We aim to be active investors by securing board roles whenever possible; this is a role that is familiar to us and helps mitigate risk to our investors by helping to shape the course of our investments Innovative yet Validated ModalitiesWe have selected five core therapeutic sectors to focus our investments: Oncology, Immunology, CV/Metabolic, CNS/Ophthalmology, and Rare/Genetic Disease For each of the above sectors we have defined various focus areas defined by a unique combination of validation, unmet need, market potential, and acquisition/public market interest We seek to limit biological and technical risk and prioritize small molecule, antibody approaches (includes mAbs, bsAbs/TCEs, ADCs, radiotherapeutics), and nucleic acid therapeutics (siRNA, ASOs) across these sectors Rigorous EvaluationWe leverage the combined scientific background of our team and our affiliates in Asia (medicinal chemistry, pharmacology, structural biology) to perform rigorous evaluation of each investment We prepare a comprehensive diligence memo for each investment that includes a thorough evaluation of the science, pipeline, finance, management, board, investors, operations, regulatory, IP, clinical development, and potential return to our investors We conduct calls with relevant Key Opinion Leaders for every opportunity to ensure we have the most informed and updated views from the leading voices in the field

At Town Hall Ventures, we seek to partner with entrepreneurs who are as passionate as we are about changing our health care system. When we invest, we will make a substantial commitment of our time, network and resources to support entrepreneurs and their investors through the ups and downs of building successful companies. It’s why we choose to invest in fewer opportunities than most and only in the most impactful - focusing all of our energy working side-by-side with our partners to create and scale the breakthrough companies that will transform health care. Our Mission Using innovation to fix health inequities. Those fortunate enough to be born in the right zip code live longer and healthier lives than those in communities next door. Systemically, people who represent diverse racial, ethnic and gender identities, especially when combined with lower socioeconomic status, experience substantially worse health outcomes in the United States. These inequities in health - physical, mental and social determinants - result in individual, community and national struggles. When we provide great health care to the least fortunate, we are benefiting our entire societal fabric. We have an opportunity to shift investment away from nice-to-have ideas to proven solutions that improve care for populations that have long been underserved. Innovations aimed at improving care have been slow to come to areas that need it most, including: primary care, mental health, addiction, end-of-life care, kidney care, maternity and newborn health. The costs of ignoring these issues are carried by everyone. Enter the mission-driven entrepreneur. Over the past few years, innovative health care delivery approaches that serve Medicare populations have begun to emerge. Entrepreneurs have brought a new focus on reinvigorating primary care and pushing care into more comfortable settings. These models are just getting started, touching only 2% of the Medicare population today, but have tremendous potential to transform health for millions more. Thanks to an improved set of incentives, similar innovation is now coming to Medicaid. Entrepreneurs are beginning to focus on the needs of this population with the goal of dramatically improving health outcomes for patients and providing value to the hospitals, managed care plans, and State and Federal governments who care for them. Companies who create effective solutions to these challenges have the opportunity to improve the lives of 120 million Americans.

Aditum Bio brings together unmatched scientific and domain expertise with agile operational capabilities. Our unique investment and operating model enables rapid company formation, planning, and execution to advance novel drug candidates into the clinic and speed their delivery to the patients in need. PROVEN INDUSTRY LEADERSHIP AND SCIENTIFIC EXPERTISE Launched by former Novartis CEO, Joe Jimenez, and former President of the Novartis Institutes for BioMedical Research, Dr. Mark Fishman, the experience of our founding executive team provides Aditum Bio with a unique lens for identifying and selecting innovative drug candidates with unrecognized potential. BETTER OUTCOMES FOR PATIENTS. FASTER RETURNS FOR INVESTORS. By singularly focusing on the translation phase of drug development, Aditum Bio efficiently identifies and develops potentially first- and best-in-class therapies for a broad array of diseases – empowering our ability to reach more patients and creating faster return for its capital investments. OUR VALUES: ROOTED IN SCIENCE, INSPIRED BY PATIENTS Aditum Bio is a new breed of biotech investment firm that is driven to translate science into the new medicines that make a meaningful difference in the lives of patients. We are a dedicated and ambitious team that is tightly aligned by a set of core values that underscore the important work we do. WE ARE PATIENT CENTRIC We have a passion to help patients, and this drives our decision making. We believe that our role is to develop therapies for patients with disorders currently neglected but which are scientifically tractable. WE ARE COLLABORATIVE We believe that we can accomplish more as a team than we can as individuals. We are respectful of each other and listen to understand. We enjoy fierce debate among ourselves to get to the right decision, but in a way that is respectful and appreciative. We pick our colleagues up when they are down. WE ARE CURIOUS We are a collection of people with high learning agility, and believe that no matter what age, we all have much to learn. We change our opinion without hesitation or embarrassment when new facts arise. We seek out the best experts in the world as advisors. WE ARE COURAGEOUS We define the single most important question to a new therapy’s success, then have the courage to answer it. We have a high emotional need to take on challenges and deliver results. We believe it is better to act on 80% of an answer than wait for the remaining 20%. We have the courage to stand up for our beliefs, but the humbleness to consider other viewpoints. FULLFILLING THE PROMISE OF SCIENCE Genetic, genomic and artificial intelligence have led to the discovery of new drug targets and therapeutic modalities; however, many drug candidates fail to be developed due to strategic decisions and high clinical trial expense. Aditum Bio stands apart in the biotech venture capital arena through our differentiated approach for identifying promising, clinic-ready therapies that offer value for underserved patient populations, in areas such as obesity, depression, substance abuse, renal disease, and infectious diseases. ACCELERATING BIOTECH COMPANY FORMATION Harnessing our experienced in-house R&D domain experts as the foundation of our agile operating model, Aditum Bio is able to accelerate the formation and ramp-up of its portfolio companies. We augment each company's newly-established, dedicated leadership team with medical and scientific experts. Operating under the Aditum Bio umbrella in a lean and efficient management structure, portfolio companies are empowered to rapidly progress newly-acquired drug candidates into Phase 2 clinical trials. LEVERAGING TECHNOLOGY FOR EFFICIENT TRIAL EXECUTION Aditum Bio’s strategic advantage extends to its proven acumen for using an array of powerful technologies and digital tools throughout its portfolio companies to support clinical trial execution at the highest level of efficiency. Through our in-house technology capabilities and our extensive partnerships with leading solutions providers, we enable therapies to advance more quickly and at lower cost than in traditional R&D models.